Molecular Health GmbH
Molecular Health - Dataome Technology
Reliable predictions to anticipate risks. Interlinked data to find new targets and design novel drugs. Real-world evidence to evaluate success. These capabilities eliminate the uncertainties that limit drug development but are data-intensive and experimentally inaccessible. Molecular Health Dataome Technology offers powerful solutions to transform drug development. By merging world-class biomedical data, AI-powered analytics, and subject matter expertise, we deliver insights that go beyond human and experimental limitations.
Most popular related searches
drug development
medical device approval
drug candidate
drug therapy
disease modeling
clinical stage
clinical trial
medical device
biomedical data
disease target
- Proprietary data capture and structure creates an unmatched and evolving knowledge base
- In-house curation by biomedical experts to link and deliver otherwise inaccessible data
- Stringent data quality assurance via highly standardized data capture and assimilation
- Tailored design of in silico disease models to connect drug therapies to patient outcomes
- Disease agnostic knowledge base with in-depth focus on CNS diseases and oncology
- Access to real-world data from millions of patients to generate and validate relevant hypotheses
- An extended, powerful portfolio of advanced analytical and AI technologies
- Extensive quality certifications and medical device approval
- Proven and published [1–3] track record of successful projects with industry, academia and regulators
Accelerate drug development and reduce costs by exploring in depth the complete data and information landscape around your product.
- Understand the biology of complex disease and identify better target-disease relationships
- Investigate molecular disease subtypes to identify and address responder patient populations
- Reveal new promising targets for the development of novel therapies
- Augment the value of pipeline drug candidates and portfolio drugs
- Optimize clinical trial structure, size, and relevant study cohorts
- Anticipate risks and mitigate failure of candidates at clinical stage